Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240040/S008

Oncomine Dx Express Test

Life Technologies Corporation · Decision date Nov 4, 2026

MEDTECHLEDGER EXPLANATIONP240040/S008

What did the FDA approve?

The FDA recorded approval on 2026-11-04 for P240040/S008, a supplement to the Oncomine Dx Express Test held by Life Technologies Corporation. The supplement is classified as a real-time process submission with a recorded reason of change to design, components, specifications or materials. The device category is a next generation sequencing oncology panel for somatic or germline variant detection, under product code PQP in the pathology specialty.

The recorded scope is narrow: approval covers Genexus Dx Software Security Patch version 6.8.2.2, intended to address vulnerabilities discovered in the Genexus Dx Software. This is a software component change within the existing application, not a new approval of the whole test system, and the source does not describe analytical or clinical performance data, affected assay functions, or the nature of the vulnerabilities. Whether the patch alters test performance or requires customer action is not stated in the available record.

FDA approval order statement

Approval for Genexus Dx Software Security Patch version 6.8.2.2 to address the vulnerabilities discovered on the Genexus Dx Software.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Pathology
Decision date
Nov 4, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240040/S008
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Nov 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P240040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240040 · Original PMA

    Oncomine Dx Express Test

  2. P240040/S008 received

    Application receipt date recorded by FDA.

  3. P240040/S005 · Related supplement

    Oncomine Dx Express Test

  4. P240040/S008 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P240040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240040

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA approvalJul 2, 2025FDA
Life Technologies CorporationPMA supplementSep 9, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Life Technologies Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7335 Executive Way, Frederick, MD, 21704

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records